Nucleoplasmin

Nucleoplasmin

Nonhistone Nuclear Phosphoproteins

Published in Lubomir S. Hnilica, Chromosomal Nonhistone Proteins, 2018

Nucleoplasmin binds histones but does not bind nucleosomes or DNA.192 Laskey and colleagues187 propose that nucleoplasmin facilitiates nucleosome assembly by shielding the positive charges on histones from the DNA phosphates. This allows the histones to combine with the DNA in an orderly manner rather than form improperly placed salt bridges. The role of phosphorylation in this process or in maintaining the structure of nucleoplasmin is not known.

Identifying effective drug combinations for patients with acute myeloid leukemia

View Article

Journal Information

Published in Expert Review of Anticancer Therapy, 2020

Musa Yilmaz, Tapan Kadia, Farhad Ravandi

AML genomes have fewer mutations than most other adult cancers. Per the Cancer Genome Atlas Research Network study, the average number of mutations per AML patient was 13, of which 5 were recurrently mutated [33]. In total, they identified 23 recurrently mutated genes in AML and broke them down into 9 categories such as signaling genes, DNA methylation genes, chromatin-modifying genes, tumor suppressor genes, cohesion complex genes, transcription factor fusions, tumor suppressor genes, nucleoplasmin, and spliceosome complex genes. Each of these categories could be thought of as a target for drug development. In addition to therapeutic implications, some of these alterations may be used for response evaluation, disease monitoring, and prognostic assessment.

Explore chapters and articles related to this topic

Nonhistone Nuclear Phosphoproteins

Identifying effective drug combinations for patients with acute myeloid leukemia